19-0480
Magnesium sulfate heptahydrate
JIS special grade, ≥99.5%
Synonym(s):
Epsom salts
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
MgSO4 · 7H2O
CAS Number:
Molecular Weight:
246.47
UNSPSC Code:
12352302
PubChem Substance ID:
EC Number:
231-298-2
MDL number:
Assay:
≥99.5%
Grade:
JIS special grade
Form:
fine crystals
InChI key
WRUGWIBCXHJTDG-UHFFFAOYSA-L
InChI
1S/Mg.H2O4S.7H2O/c;1-5(2,3)4;;;;;;;/h;(H2,1,2,3,4);7*1H2/q+2;;;;;;;;/p-2
SMILES string
O.O.O.O.O.O.O.[Mg++].[O-]S([O-])(=O)=O
grade
JIS special grade
vapor density
<0.01 (vs air)
assay
≥99.5%
form
fine crystals
availability
available only in Japan
pH
5.0-8.0 (50 g/L)
Looking for similar products? Visit Product Comparison Guide
Storage Class
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ran D Goldman et al.
Pediatrics, 132(6), e1634-e1641 (2013-11-28)
Vaso-occlusive episodes (VOEs) are the most common complication of sickle cell disease in children. Treatment with magnesium seems to improve cellular hydration and may result in reduced vaso-occlusion. This study aimed to determine if intravenous (IV) magnesium sulfate (MgSO4) reduces
Oluwakemi Badaki-Makun et al.
Pediatric blood & cancer, 61(6), 1049-1054 (2014-01-21)
Multiple recent Sickle Cell Disease studies have been terminated due to poor enrollment. We developed methods to overcome past barriers and utilized these to study the efficacy and safety of intravenous magnesium for vaso-occlusive crisis (VOC). We describe the methods
E S Bain et al.
BJOG : an international journal of obstetrics and gynaecology, 121(5), 595-603 (2014-01-07)
To evaluate a slower (compared with a standard) infusion rate of the loading dose of magnesium sulphate for preterm fetal neuroprotection as a strategy to reduce maternal adverse effects. Randomised controlled trial. South Australian maternity hospital. Fifty-one women at <30
Chris Chin
Artificial organs, 37(1), 100-102 (2013-01-12)
Congenital heart disease (CHD) is relatively common and there are treatment options for virtually every form of CHD. With good care, the majority of babies can survive to adulthood; however, CHD remains a significant cause of death in infancy and
Karen J Gibbins et al.
Obstetrics and gynecology, 121(2 Pt 1), 235-240 (2013-01-25)
Clinical trials support the efficacy and safety of magnesium sulfate for cerebral palsy prevention. We evaluated the implementation of a clinical protocol for the use of magnesium for cerebral palsy prevention in our large women's hospital, focusing on uptake, indications
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service